By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. (VTGN)

NASDAQ Currency in USD
$3.50
-$0.07
-1.96%
Last Update: 11 Sept 2025, 20:00
$107.38M
Market Cap
-2.85
P/E Ratio (TTM)
Forward Dividend Yield
$1.90 - $3.88
52 Week Range

VTGN Stock Price Chart

Explore VistaGen Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze VTGN price movements and trends.

VTGN Company Profile

Discover essential business fundamentals and corporate details for VistaGen Therapeutics, Inc. (VTGN) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

21 Jun 2011

Employees

48.00

CEO

Shawn K. Singh

Description

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

VTGN Financial Timeline

Browse a chronological timeline of VistaGen Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 11 Feb 2026

Upcoming earnings on 6 Nov 2025

EPS estimate is -$0.52, while revenue estimate is $157.25K.

Earnings released on 7 Aug 2025

EPS came in at -$0.47 matching the estimated -$0.47, while revenue for the quarter reached $244.00K , beating expectations by +13.14%.

Earnings released on 17 Jun 2025

EPS came in at -$0.43 surpassing the estimated -$0.52 by +17.31%, while revenue for the quarter reached -$15.00K , missing expectations by -107.17%.

Earnings released on 13 Feb 2025

EPS came in at -$0.46 surpassing the estimated -$0.48 by +4.17%, while revenue for the quarter reached $234.00K , beating expectations by +28.57%.

Earnings released on 7 Nov 2024

EPS came in at -$0.42 falling short of the estimated -$0.40 by -5.00%, while revenue for the quarter reached $183.00K , missing expectations by -23.75%.

Earnings released on 13 Aug 2024

EPS came in at -$0.35 surpassing the estimated -$0.41 by +14.63%, while revenue for the quarter reached $84.00K , missing expectations by -72.00%.

Earnings released on 11 Jun 2024

EPS came in at -$0.25 surpassing the estimated -$0.34 by +26.47%, while revenue for the quarter reached $197.30K , missing expectations by -1.35%.

Earnings released on 13 Feb 2024

EPS came in at -$0.22 surpassing the estimated -$0.31 by +29.03%, while revenue for the quarter reached $411.40K , beating expectations by +105.70%.

Earnings released on 9 Nov 2023

EPS came in at -$0.66 surpassing the estimated -$0.68 by +2.94%, while revenue for the quarter reached $278.00K , beating expectations by +50.60%.

Earnings released on 10 Aug 2023

EPS came in at -$0.94 falling short of the estimated -$0.86 by -9.30%, while revenue for the quarter reached $177.00K , missing expectations by -1.67%.

Earnings released on 22 Jun 2023

EPS came in at -$1.75 falling short of the estimated -$1.50 by -16.67%, while revenue for the quarter reached $175.60K , missing expectations by -2.23%.

Stock split effective on 7 Jun 2023

Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 7 Feb 2023

EPS came in at -$1.50 surpassing the estimated -$1.80 by +16.67%, while revenue for the quarter reached $179.60K , beating expectations by +99.56%.

Earnings released on 10 Nov 2022

EPS came in at -$2.40 matching the estimated -$2.40, while revenue for the quarter reached -$892.50K , missing expectations by -387.86%.

Earnings released on 11 Aug 2022

EPS came in at -$3.00 falling short of the estimated -$2.70 by -11.11%, while revenue for the quarter reached $310.10K , beating expectations by +29.95%.

Earnings released on 23 Jun 2022

EPS came in at -$2.40 falling short of the estimated -$1.80 by -33.33%, while revenue for the quarter reached $38.90K , missing expectations by -88.51%.

Earnings released on 10 Feb 2022

EPS came in at -$1.50 surpassing the estimated -$2.40 by +37.50%, while revenue for the quarter reached $357.90K , beating expectations by +5.68%.

Earnings released on 10 Nov 2021

EPS came in at -$2.10 falling short of the estimated -$1.50 by -40.00%, while revenue for the quarter reached $358.00K , beating expectations by +1.01%.

Earnings released on 12 Aug 2021

EPS came in at -$1.20 surpassing the estimated -$1.50 by +20.00%, while revenue for the quarter reached $354.10K , beating expectations by +0.03%.

Earnings released on 29 Jun 2021

EPS came in at -$6.01 falling short of the estimated -$1.50 by -300.67%, while revenue for the quarter reached $441.90K .

Earnings released on 11 Feb 2021

EPS came in at -$2.10 falling short of the estimated -$1.50 by -40.00%, while revenue for the quarter reached $313.60K , beating expectations by +1.01%.

Earnings released on 12 Nov 2020

EPS came in at -$1.50 falling short of the estimated $0.60 by -350.00%, while revenue for the quarter reached $334.00K , beating expectations by +21.21%.

VTGN Stock Performance

Access detailed VTGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run